Gland Pharma's Dundigal Facility Passes FDA Inspection: A Step Towards Compliance

Establishment Inspection Report has been issued by the US Food and Drug Administration (US FDA) for Gland Pharma's facility at Dundigal in Hyderabad which indicates that the recent concluded inspection was successfully closed.

The US FDA conducted a surprise Good Manufacturing Practices (GMP) inspection at the Dundigal facility from July 22 to July 25, 2024, which concluded with two procedural observations.

The issuance of the EIR confirms that Gland Pharma has adequately addressed the observations, reaffirming its commitment to maintaining high-quality manufacturing standards.

 

Source: Business Standard

Gland Pharma Limited

BizNews IndiaEstablishment Inspection Report has been issued by the US Food and Drug Administration (US FDA) for Gland Pharma's facility at Dundigal in Hyderabad which indicates that the recent concluded inspection was successfully closed.

Establishment Inspection Report has been issued by the US Food and Drug Administration (US FDA) for Gland Pharma's facility at Dundigal in Hyderabad which indicates that the recent concluded inspection was successfully closed.

Establishment Inspection Report has been issued by the US Food and Drug Administration (US FDA) for Gland Pharma's facility at Dundigal in Hyderabad which indicates that the recent concluded inspection was successfully closed.The US FDA conducted a surprise Good Manufacturing Practices (GMP) inspection at the Dundigal facility from July 22 to July 25, 2024, which concluded with two procedural observationThe US FDA conducted a surprise Good Manufacturing Practices (GMP) inspection at the Dundigal facility from July 22 to July 25, 2024, which concluded with two procedural observations.

The issuance of the EIR confirms that Gland Pharma has adequately addressed the observations, reaffirming its commitment to maintaining high-quality manufacturing standards.

Source: Business Standard

Gland Pharma Limited

BizNews India